AbstractHypoxia is an inherent physiologic barrier in the microenvironment of solid tumor and has badly restricted the therapeutic effect of photodynamic therapy (PDT). Meanwhile, the photosensitizer (PS) agents used for PDT applications regularly encounter the tiresome aggregation‐caused quenching effect that seriously decreases the production efficiency of cytotoxic reactive oxygen species. The aggregation‐induced emission (AIE) PSs with antiquenching characteristics in the aggregate state are considered as a promising tool for achieving highly efficient PDT applications, and plenty of studies have widely demonstrated their advantages in various diseases. Herein, the recent progress of AIE PSs in the battle of antitumor hypoxia issue is summarized and the practical molecular principles of hypoxia‐overcoming AIE PSs are highlighted. According to the hypoxia‐overcoming mechanism, these representative cases are divided into low O₂‐dependent (type I PDT) and O₂‐dependent tactics (mainly including O₂‐enrichment type II PDT and combination therapy). Furthermore, the underlying challenges and prospects of AIE PSs in hypoxia‐overcoming PDT are proposed and thus expect to promote the next development of AIE PSs.